Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug developer Endo Pharmaceuticals Holdings (NASDAQ:ENDP) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Endo's business and see what CAPS investors are saying about the stock right now.

Endo facts

Headquarters (Founded)

Chadds Ford, Pa. (1997)

Market Cap

$1.89 Billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$1.31 Billion

Management

CEO David Holveck (Since 2008), CFO Edward Sweeney (Since 2008)

Return on Capital (Average, Past Three Years)

18.2%

Competitors

Pfizer (NYSE:PFE), Merck (NYSE:MRK)

CAPS members bullish on ENDP also bullish on

Johnson & Johnson (NYSE:JNJ), General Electric (NYSE:GE)

CAPS members bearish on ENDP also bearish on

Baidu (NASDAQ:BIDU), Ambac Financial (NYSE:ABK)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 347 of the 364 members who have rated Endo -- 95% -- believe the stock will outperform the S&P 500 going forward. These bulls include Trimalerus, who is ranked in the top 0.05% of our community, and the third-ranked member in all of CAPS tenmiles.

Last month, Trimalerus followed one of CAPS' leaders and highlighted Endo as a healthy play:

This stock has good profitability and looks to be a good buy under $18. Obama has promised to have our Healthcare System overhauled by the end of the year and this is one stock that should see a benefit. Also tenmiles one of my favorite members just picked this to outperform. Crowd sourcing rocks!

In the aforementioned pitch from tenmiles, Endo gets tapped as a particularly potent portfolio-pain killer: "Adding a little Percocet to the portfolio. Pharma dealing with various pain control products offers strong balance sheet with high ROE; likely to show relative strength later in the summer in advance of FDA decision on marketing application for NEBIDO -- buyer around $18."

What do you think about Endo Pharmaceuticals, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 130,000 investors are waiting to hear what you have to say. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Pfizer is a Motley Fool Inside Value pick, Johnson & Johnson is a choice of Income Investor, and Baidu is a Rule Breakers recommendation. The Fool owns shares of Pfizer. The Fool's disclosure policy always gets a perfect score.